Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2021 08:00 ET | Source: Vincerx Pharma, Inc.

Vincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

PALO ALTO, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
December 11, 2021 15:30 ET | Source: Vincerx Pharma, Inc.

Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of disease Vincerx hosting KOL webinar today, Saturday, December...
December 07, 2021 08:00 ET | Source: Vincerx Pharma, Inc.

Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma

PALO ALTO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
December 06, 2021 08:00 ET | Source: Vincerx Pharma, Inc.

Vincerx Pharma Hosting Key Opinion Leader Webinar on VIP152 Data Presented at the American Society of Hematology Annual Meeting

PALO ALTO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
November 12, 2021 08:00 ET | Source: Vincerx Pharma, Inc.

Vincerx Pharma Reports Third Quarter 2021 Financial Results and Provides a Corporate Update

Advancing Phase 1b study of VIP152 in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors Phase 1b dose escalation study of VIP152 in patients with CLL...
November 04, 2021 09:01 ET | Source: Vincerx Pharma, Inc.

Vincerx Pharma Announces Presentations at the American Society of Hematology Annual Meeting

PALO ALTO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
September 16, 2021 07:30 ET | Source: Vincerx Pharma, Inc.

Vincerx Pharma Announces $50 Million Private Placement

PALO ALTO, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
September 07, 2021 08:00 ET | Source: Vincerx Pharma, Inc.

Vincerx Pharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

PALO ALTO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
August 12, 2021 16:05 ET | Source: Vincerx Pharma, Inc.

Vincerx Pharma Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

First patient dosed in Phase 1b study of VIP152 in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors Phase 1b dose escalation study of VIP152 in...
June 28, 2021 08:00 ET | Source: Vincerx Pharma, Inc.

Vincerx Pharma Announces Inclusion in Russell 3000® and Microcap® Indexes

PALO ALTO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right